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E-mail: jdelgado@clinic.catGenetically modifying autologous T cells to express an anti-
CD19 chimeric antigen receptor (CAR) has shown impressive
response rates for the treatment of CD19+ B cell malignancies
in several clinical trials (CTs). Making this treatment available
to our patients prompted us to develop a novel CART19
based on our own anti-CD19 antibody (A3B1), followed by
CD8 hinge and transmembrane region, 4-1BB- and CD3z-
signaling domains. We show that A3B1 CAR T cells are high-
ly cytotoxic and specific against CD19+ cells in vitro, inducing
secretion of pro-inflammatory cytokines and CAR T cell pro-
liferation. In vivo, A3B1 CAR T cells are able to fully control
disease progression in an NOD.Cg-Prkdcscid Il2rdtm1Wjl/SzJ
(NSG) xenograph B-ALL mouse model. Based on the pre-clin-
ical data, we conclude that our CART19 is clearly functional
against CD19+ cells, to a level similar to other CAR19s
currently being used in the clinic. Concurrently, we describe
the implementation of our CAR T cell production system, us-
ing lentiviral vector and CliniMACS Prodigy, within a me-
dium-sized academic institution. The results of the validation
phase show our system is robust and reproducible, while
maintaining a low cost that is affordable for academic institu-
tions. Our model can serve as a paradigm for similar institu-
tions, and it may help to make CAR T cell treatment available
to all patients.134 Molecular Therapy: Methods & Clinical Development Vol. 12 March
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Genetically modifying autologous T cells to express chimeric antigen
receptors (CARs), thus redirecting them to eliminate tumor cells, is a
new and revolutionary therapeutic modality for cancer treatment
and, in particular, for CD19+ B cell malignancies.1–9
CARs are composed of an extracellular region responsible for binding
to a particular antigen and an intracellular region that promotes T cell
cytotoxic activity and proliferation. CAR binding to the selected an-
tigen is usually mediated by a single-chain variable fragment (scFv)
of a monoclonal antibody. The scFv-derived region results in a me-
dium- to high-affinity and major histocompatibility complex
(MHC)-independent interaction of the CAR with its ligand. As a
second generation CAR, this scFv is combined with an intracellular2019 ª 2018 The Authors.
vecommons.org/licenses/by/4.0/).
www.moleculartherapy.orgco-stimulatory domain (usually CD28 or 4-1BB) and a pro-activator
cytotoxic domain (CD3z).10–12
After initial disappointing results with first-generation CARs, the
most recent clinical trials with second-generation anti-CD19 CAR
T cells have shown remarkable results in patients with chronic lym-
phocytic leukemia, non-Hodgkin’s lymphoma, and acute lymphoid
leukemia (ALL), reviewed in Wang et al.8 and Lorentzen and
Straten.13 Several academic groups, including the University of
Pennsylvania, Memorial Sloan Kettering Cancer Center, the Na-
tional Cancer Institute, and the Fred Hutchinson Cancer Research
Center, pioneered these seminal studies using slightly different CAR
constructs in terms of ScFv sequence, co-stimulatory domain, and
transmembrane-hinge region. These CARs are currently under
evaluation in a number of international multi-center clinical trials.
Two of them, tisagenlecleucel (Kymriah, Novartis) and axicabta-
gene ciloleucel (Yescarta, Kyte-Gilead), have been approved by
the U.S. Food and Drug Administration, European Union (EU),
and Canada for clinical use. Regarding efficacy, response rates
range from 50% to 85%, depending on the type of B cell malignancy
and CAR construct, with quite remarkable disease-free and overall
survival.13 In terms of safety, patients who respond to therapy
usually develop persistent B cell aplasia and transitory cytokine
release syndrome, which could be severe in a small proportion of
patients.14
Despite these striking results, this therapeutic approach is currently
available only in a handful of centers. With Kymriah and Yescarta
approval for certain diseases, this treatment will become available
in multiple places (in and outside the United States), although the
high cost can still limit access. For these reasons, we decided to
develop our own CAR construct targeting CD19 (ARI-0001) that
comprises an scFv of our own anti-CD19 monoclonal antibody
(mAb) (A3B1) plus the 4-1BB- and CD3z-signaling domains. This
paper shows the results of pre-clinical work as well as the description
of our production system for ARI-0001 cells, focusing on the results of
the validation phase of our clinical trial (CART19-BE-01), which has
enrolled and treated more than 20 patients and is currently ongoing.
Our work demonstrates the feasibility of producing CAR T cells in
medium-sized academic institutions.
RESULTS
Validation of Anti-hCD19 A3B1 mAb
Our anti-hCD19 A3B1 mAb has been used in previous studies.15
Nevertheless, we designed a set of experiments to further confirm
its specificity. As shown in Figure S1A, anti-hCD19 A3B1 reacted
against the mouse lymphoma cell line 300.19 transfected with
hCD19, but not with untransfected cells. Anti-hCD19 A3B1 also
reacted with a subset of human peripheral blood cells, as expected
(Figure S1B). Anti-hCD19 A3B1 reacted with B cell lines Raji and
Daudi, while no reactivity was observed when T, myeloid, or natural
killer (NK) cell lines were used, consistent with the pattern of CD19
expression (Figure S1C). Furthermore, we show that pre-incubation
of Daudi cells with the anti-CD19 FMC63 antibody blocked the bind-Molecularing of A3B1, confirming its specificity for CD19 (Figure S1D). These
data also suggest that A3B1 and FMC63 antibodies have overlapping
epitopes. Finally, a band of around 100 kDa was precipitated from
Daudi cells using anti-hCD19 A3B1, consistent with the expectedmo-
lecular weight of CD19 (Figure S1E). All these data together indicate
that A3B1 is a highly sensitive and specific antibody for human CD19
protein.
In Vitro Evaluation of ARI-0001 Efficacy
The scFv of anti-CD19 A3B1 antibody was cloned in frame with the
rest of the CAR-signaling domains in a lentiviral vector (pCCL) (Fig-
ure 1A). For the evaluation of CAR19 A3B1 efficacy, peripheral blood
mononuclear cells (PBMCs) isolated from buffy-coats were activated
using CD3 and CD28 dynabeads and subsequently transduced using
CAR19-containing lentivirus. After an expansion period, the expres-
sion of CAR19 on T cells was confirmed by flow cytometry (Fig-
ure S2A). The percentage of ARI-0001 cells varied between 20%
and 56%, depending on the experiment.
Cytotoxicity of ARI-0001 cells was measured by the in vitro erad-
ication of the CD19-positive NALM6 cell line. For this purpose,
we developed a flow cytometry-based assay to quantify the number
of viable, CD19+ cells (see Materials and Methods and Figure S3).
NALM6 cells were almost completely eliminated after 16 hr of co-
culture, even after very low effector (E):target (T) ratios (1 effector
cell for every 8 target cells). We also observed a minor cytotoxic ef-
fect of untransduced (UT) cells due to alloreactivity (Figure 1B).
Target cell specificity was also tested by measuring the survival
of a CD19-negative HL60 cell line in co-culture with ARI-0001
cells. As expected, no ARI-0001-mediated killing was appreciated
in this case (Figure S2B). The cytotoxicity of ARI-0001 cells
was also tested against primary B cell acute lymphocytic leukemia
(B-ALL) cells, demonstrating similar efficacy (Figure S2C). All
these data together indicate that our ARI-0001 cells exhibit a potent
and specific cytotoxic effect against CD19-positive cells in vitro.
To better characterize ARI-0001 cell response upon CD19 binding,
cell proliferation was measured by using a standard carboxyfluores-
cein diacetate succinimidyl ester (CFSE) assay at the 96-hr time point.
Antigen binding should be able to promote ARI-0001 cell expansion
in order to eliminate a tumor in vivo. As shown in Figure 1C, ARI-
0001 cells proliferated in contact with the CD19+ NALM6 cell line
and in response to interleukin-2 (IL-2) (to a minor extent). No pro-
liferation was observed in the absence of stimulus or in contact
with a CD19-negative cell line (K562), confirming that cell prolifera-
tion was mediated by CD19 recognition.
Finally, ARI-0001 cell production of cytokines was measured in the
supernatant of effector-target cell co-cultures after 16 hr and
analyzed using an ELISA. Cytokine levels from co-cultures using
ARI-0001 or UT cells were compared (Figure 1D). While UT cells
did not show an increase in interferon (IFN)g and tumor necrosis
factor alpha (TNF-a), ARI-0001 cells showed a significant increase
in these two pro-inflammatory cytokines. As expected, a very minorTherapy: Methods & Clinical Development Vol. 12 March 2019 135
Figure 1. ARI-0001 Anti-tumor Activity In Vitro
(A) Diagram of A3B1 CAR19 construct. (B) Cytotoxicity assay of CART19 cells versus NALM6 cells at the 16-hr time point. Percent target surviving cells, relative to untreated,
is shown (mean of 3 experiments ± SEM). Panels on the right show representative flow cytometry plots at E:T ratio = 1:8. (C) CAR19 T cell proliferation in vitromeasured by
CFSE assay at the 96-hr time point. Panels on the left show representative flow cytometry images. Panel on the right shows quantification of the proliferation index (PI). Mean
of 4 experiments ± SEM is shown. (D) Cytokine production (IFNg, TNF-a, and IL-10) of CART19 cells in co-culture with NALM6 cells at the 16-hr time point, measured by
ELISA. Mean of 3 experiments ± SEM is shown. *Statistical significance, p < 0.05; n.s., not statistically significant.
Molecular Therapy: Methods & Clinical Developmentand not significant increase in the anti-inflammatory cytokine IL-10
was observed.
In Vivo Evaluation of ARI-0001 Efficacy
To evaluate the efficacy of the CART19 cells in vivo, we performed a
xenograft experiment in NOD.Cg-Prkdcscid Il2rdtm1Wjl/SzJ (NSG)
mice.
Mice were randomly allocated to the administration of vehicle (A),
UT cells (B), ARI-0001 cells (C), NALM6 cells (D), NALM6 plus
UT cells (E), and NALM6 plus ARI-0001 cells (F). Mice correspond-
ing to groups D–F were inoculated with NALM6-Luc + GFP +
(CD19+) cells through their tail vein on day 1. On day 4, mice136 Molecular Therapy: Methods & Clinical Development Vol. 12 Marchbelonging to groups B, C, E, and F were infused with either UT cells
or ARI-0001 cells.
As shown in Figure 2A, disease progression was clearly observed dur-
ing a period of 2 weeks following NALM6 cell infusion in the NALM6
group (5 of 6 animals progressed) and the NALM6 + UT cell group
(4 of 4 animals progressed). However, no disease was detected in
any of the mice belonging to the NALM6 + ARI-0001 group (0 of 6
mice progressed). The experiment was completed and the animals
sacrificed at days 16–17, when the animals belonging to the
NALM6 group started to show evident signs of disease. To confirm
bioluminescence imaging data, bone marrow and blood cells were
processed for flow cytometry. Anti-human CD19 staining confirmed2019
Figure 2. ARI-0001 Anti-tumor Activity In Vivo
(A) Upper panel shows a timeline of experimental design.
Lower panels show bioluminescence images showing
disease progression at different days. Animals indicated by
a pound sign were sacrificed at day 16 due to advanced
disease progression. The rest of the animals were sacri-
ficed at day 17. (B) Detection of tumor (CD19+) cells in
the bone marrow of mice shown in (A) (mean ± SD).
(C) Detection of tumor (CD19+) cells in blood.
www.moleculartherapy.orgthe presence of tumor cells in the NALM6 and NALM6 + UT groups,
while no significant percentages of tumor cells were detected in the
other groups (Figures 2B and 2C) compared to control.Comparison of Cytotoxic Activity of ARI-0001 Cells to Other
CART19 Constructs
To investigate how ARI-0001 cells, which contain the scFv from the
A3B1 antibody, perform compared to other CART19 cells currently
in use for the treatment of CD19+ malignancies, we cloned the
scFv of the FMC63 antibody in our vector. The rest of the CAR
construct remained the same, so we could directly compare the effi-
ciency of both scFv fragments. For these analyses, we transduced
PBMCs with a lentivirus containing each one of the CAR constructs.
CAR19 protein expression was confirmed bywestern blot (Figure 3A).
The cytotoxic activity of A3B1 and FMC63 CAR T cells was then
compared in vitro. Figure 3B demonstrates no significant difference
in cytotoxic potency between the CARs.
The two CAR constructs were then compared in vivo. For this exper-
iment, the disease was allowed to progress before administering CAR
T cells. The complete experimental design is depicted in Figure 3C. As
shown in Figure 3C, NALM6 cell engraftment was detected by biolu-
minescence imaging 6 days after injecting NALM6 cells in all mice.
Following the administration of UT T cells, disease continued toMolecular Therapy: Methods &progress in the NALM6 + T group, while A3B1
and FMC63 CAR T cells progressively eliminated
the tumor. Animals in the NALM6 + T group
were sacrificed between days 11 and 12 due to
disease progression. Quantification of the biolu-
minescence images indicated no statistical differ-
ence in the capacity of A3B1 and FMC63 CAR
T cells to eliminate the tumor cells (Figure S4).
Finally, flow cytometry performed on blood of
these mice, taken at day 12 after T cell injection,
confirmed no detectable disease in the blood of
treated mice and T cell expansion (Figure 3D).
The level of disease eradication and T cell expan-
sion was equal between the two groups (A3B1
and FMC63).
Altogether, these data indicate that A3B1 scFv
is capable of binding to CD19, triggering acytotoxic response, and eliminating a tumor to a level similar to
FMC63.
Large-Scale CAR19 Lentivirus Production
Having demonstrated the efficacy and specificity of ARI-0001 cells
in vivo and in vitro, we proceeded to set up and standardize the con-
ditions for patient-scale ARI-0001 cell production.
To produce enough lentiviral supernatant to complete the clinical
trial, we scaled up our virus production method, and we conducted
the entire process inside a clean room facility following Good
Manufacturing Practice (GMP) guidelines, although lentiviral super-
natant was considered to be an intermediate reagent in terms of drug
agency approval. An overview of the process highlighting the critical
steps is depicted in Figure 4. Each lot consisted of 4 L of unconcen-
trated virus and the production time per lot was 12 days. HEK293T
was used as the packaging cell line. Before starting production,
HEK293T master and working cell banks were prepared, so all lots
were produced using HEK293T from the same passage.
For each production, we first expanded HEK293T in T175 flasks for
2 passages (expanding from 80  106 cells to a minimum of 2,829 
106 cells). Cells were then transferred to four 10-layer CellStacks cell
culture chambers (Corning) and one 1-layer CellStack to control for
cell proliferation. Plasmid transfection was carried out the next dayClinical Development Vol. 12 March 2019 137
Figure 3. Comparison of Anti-tumor Activity of A3B1- and FMC63-based CAR T Cells
(A) Detection of chimeric antigen receptor (CAR) expression by western blot. (B) Cytotoxicity assay of CART19 cells versus NALM6 cells after 4 hr of co-culture. Percent target
surviving cells, relative to untreated, is shown (mean of 3 experiments ± SEM). (C) Upper panel shows a timeline of experimental design (*Im, bioluminescent image; *Bl, blood
sample). Lower panels show bioluminescence images showing disease progression at different days. (D) Detection of tumor (GFP+) cells and CD3+ cells in blood by flow
cytometry. Control, control mice (no tumor or T cells were injected).
Molecular Therapy: Methods & Clinical Developmentusing 3.86 mg polyethylenimine (PEI), 763 mg transfer vector,
377 mg pMDLg-pRRE, 188 mg pRSV-Rev, and 221 mg pMD2.G
per liter. Viral supernatants were collected 2 days later and clarified
using a 0.45-mm polyvinylidene fluoride (PVDF) membrane. 4 L
viral supernatant was finally concentrated and diafiltered using
KrosFlo Research IIi Tangential Flow Filtration System (Spectrum
Labs) and 500 kD modified polyethersulfone (mPES) hollow fibers.
2 L PBS was used as diafiltration buffer. Each lot was concentrated
to 100 mL, aliquoted in 10-mL bags, and kept at 80C until use.138 Molecular Therapy: Methods & Clinical Development Vol. 12 MarchSmaller aliquots were also kept for viral titer determination and ste-
rility and purity analyses. For protocol validation, 3 viral lots were
produced and analyzed. The results of analyses performed on these
3 lots are shown in Table 1. Viral titer of frozen-concentrated virus
ranged between 1.1 and 2.2  108 transducing units (TU)/mL.
Quality control testing indicated that all three lots were negative
for bacterial-fungal growth, mycoplasma, or replication-competent
lentivirus (RCL). Virus identity was also confirmed by PCR ampli-
fication of principal virus components.2019
Figure 4. Diagram Depicting the Main Steps of Large-Scale CAR19 Lentivirus Production as Currently Established at Hospital Clı́nic de Barcelona
www.moleculartherapy.orgARI-0001 Cell Production
ARI-0001 cells were produced using CliniMACS Prodigy (Miltenyi
Biotec). Apheresis products were subjected to CD4- and CD8-positive
selection, and 100  106 T cells were then cultured and activated us-
ing anti-CD3 and anti-CD28 antibodies. At 24 hr after activation,
cells were transduced with CAR19 lentivirus (MOI = 10). Cells
were cultured in media containing IL-7 and IL-15 until the desired
cell number was reached (typically 8–9 days). T cell expansion with
IL-7 and IL-15 has been shown to result in a much more TN and
TSCM phenotype than when using expansion with IL-2, which favors
TEFF.
16 The product was collected in NaCl 0.9% + 0.5% human serum
albumin (HSA). To test the consistency and robustness of our pro-
duction method, we conducted three procedures using apheresis
products from three different healthy donors. Our goal was to reach
a minimum of 35  106 ARI-0001 cells and R20% transduction
efficiency.
As shown in Figure 5, the expansion time varied between 8 and
11 days. Run ARI0001/01 was allowed to proceed to day 11 to testMolecularProdigy’s T cell expansion capacity, but the rest of the runs were
stopped earlier (day 9 and day 8, respectively), since the minimum
number of cells required was already reached. A mean of 3,780 
106 total cells was obtained, and the percentage of transduction aver-
aged 35.8% at the time the cell expansion was terminated. Therefore,
the acceptance criteria were reached in all three procedures. A full list
of the quality tests conducted on the final products and the acceptance
criteria that were defined for each of them is provided in Table 2. As
shown in the same table, all ARI-0001 products obtained met the
acceptance criteria established for all parameters regarding purity,
safety, and potency. The results of in vitro cytotoxicity assay (potency)
performed with the ARI-0001 final products are shown in Figure S5.
DISCUSSION
The use of genetically modified autologous T cells that express an
anti-CD19 CAR (CART19) has shown impressive response rates
for the treatment of CD19-positive B cell malignancies in several clin-
ical trials. However, bringing this experimental treatment to commer-
cialization phase is a lengthy process. The urgent need to make thisTherapy: Methods & Clinical Development Vol. 12 March 2019 139
Table 1. Results and Quality Controls of GMP-Grade Viral Productions of 3 Supernatant Lots
Parameter Method Acceptance Criteria Lot 1 Lot 2 Lot 3
Appearance visual inspection yellowish liquid solution cloudy liquid solution cloudy liquid solution cloudy liquid solution
Viral titer limiting dilution >3.75  107 TU/mL 2.29  108 TU/mL 1.68  108 TU/mL 1.10  108 TU/mL
Sterility microbial growth sterile sterile sterile sterile
Mycoplasma PCR absent absent absent absent
Identity PCR positive positive positive positive
RCL (replication-competent lentivirus) real-time PCR absent absent absent absent
Molecular Therapy: Methods & Clinical Developmenttreatment available to our patients prompted us to develop a new
anti-CD19 CAR based on our own anti-CD19 antibody (A3B1).
There are many different CART19 constructs currently being evalu-
ated in pre-clinical as well as in clinical studies.12 We decided to
use a second-generation CAR with 4-1BB co-stimulator, based on
the CAR developed by UPenn-CHOP, since it has shown a signifi-
cantly longer persistence of CART19 cells both in mice and in hu-
mans.17,18 We saw that our A3B1-CART (ARI-0001) cells were able
to efficiently and specifically eliminate CD19-positive cells, both
in vitro and in vivo, triggering a pro-inflammatory cytokine response
and T cell proliferation—all necessary events for clinical efficacy. Our
construct incorporates the scFv belonging to the A3B1 anti-CD19
antibody, which has never been used for therapeutic purposes before.
We demonstrated that the in vitro and in vivo efficacy of ARI-0001
cells was similar to other constructs currently in use. This indicates
that A3B1 antibody has a good avidity for its epitope and is consistent
with the fact that CD19 possesses a single dominant epitope or adja-
cent epitopes.19 Thus, a change of scFv might not be as determinant
for a good CAR19 response as with other target proteins.
Having shown that ARI-0001 cells perform as expected in pre-clinical
studies and their in vitro effectivity might be comparable to other
CART19 constructs currently used, the next step was to set up the
infrastructure and the procedures to be able to move ARI-0001 cells
to the clinic. This represents a considerably big enterprise for a rela-
tively small publicly funded institution, but its success relies on two
important facts: (1) involvement of a large number of groups from
different disciplines and organizations in the project, which included
basic scientists, hemato-oncology and immunotherapy clinical units,
and GMP facilities with expertise in cellular therapies; and (2) CARs
other than anti-CD19 that are currently being developed easily at the
pre-clinical stage by several basic science labs in the Hospital Clínic-
influenced area. Therefore, the platform created to transfer the anti-
CD19 CAR from bench to bedside will also serve to promote quicker
and easier transfer of other CARs to clinic.
ARI-0001 cell production includes two independent procedures: (1)
large-scale vector production, and (2) ex vivo transduction and
expansion of genetically engineered T cells. For vector production,
we chose a third-generation lentiviral vector, since it is considered
to be safer for patients than retroviral vectors or second-generation140 Molecular Therapy: Methods & Clinical Development Vol. 12 Marchlentivirus.20–22 However, it is important to note that a third-genera-
tion lentiviral system is the least efficient of the three, in terms of
quantity of viral particles per milliliter obtained, thus increasing the
cost of the process. Large-scale lentivirus production can constitute
a bottleneck of CAR T cell production. Many different cell culture
systems can be used, from regular T175 flasks for adherent cultures
to bioreactors. We decided to use an intermediate system, similar
to a previously described method,23,24 consisting of expanding
HEK293T in T175 and then transferring to ten-layer flasks with
1-L capacity each for cell transfection and viral supernatant collec-
tion. We produced viral batches of 4-L unconcentrated virus each,
which allowed the transduction of 8 patients/viral batch. The viral
titer obtained was in range with what has been reported by other viral
production facilities, reviewed in Merten et al.25 There is an obvious
limit in the capacity of scaling up this method. Therefore, depending
on the number of patients that are planned to be treated per year,
other systems, including the use of bioreactors and cell suspension
systems, should be considered.26,27
There are many different systems currently being used for the ex vivo
transduction and expansion of CAR T cells.28,29We decided to use the
CliniMACS Prodigy system for the production of ARI-0001 cells,
since it offers two key advantages that fitted well with our production
model: (1) CliniMACS Prodigy is a semi-automated system that
allows magnetic cell separation, cell activation, transduction, and
expansion in a single machine; and (2) it is a closed GMP-compliant
system, bypassing the need to conduct the whole process inside a
specific GMP gene therapy clean room. Although the CliniMACS
Prodigy also has some disadvantages compared to other technologies
available, i.e., WAVE expansion system allows for a significantly
higher T cell expansion and process adaptability,30 it was shown to
be a robust and reproducible procedure in our hands.
In conclusion, we have developed a novel anti-CD19 CAR construct
based on a well-defined design (the UPenn-CHOP proposal), con-
formed by an scFv of our own anti-CD19 mAb (A3B1) plus the
4-1BB- and CD3z-signaling domains. After positively fulfilling
pre-clinical experiments and demonstrating robust and reproducible
lentivirus and ARI-0001 cell production, a pilot clinical trial
(CART19-BE-01, ClinicalTrials.gov: NCT03144583) for the treat-
ment of CD19-positive malignancies was recently launched in
2017 at Hospital Clínic and Hospital Sant Joan de Déu in Barcelona2019
Figure 5. Results of 3 Validation Processes of ARI-0001 Cell Production
Using Healthy Donors
(A) Total cell number at different time points. (B) Percentage of CAR19-expressing
cells at different time points.
www.moleculartherapy.org(Spain) and is now ongoing. Current results of more than 10 ARI-
0001 clinical grade products, developed for patients enrolled in
ClinicalTrials.gov: NCT03144583, show characteristics of equiva-
lence to the products presented here corresponding to the validation
step (unpublished data). Taking all these data together, this work
demonstrates that ARI-0001 cell production is robust, reproducible,
and affordable for academic institutions that try to introduce this
effective immunotherapy to their patients.MATERIALS AND METHODS
Donors, Cell Lines, and A3B1 Anti-CD19 mAb
All protocols were approved by the corresponding Institutional Re-
view Board. Healthy donor blood buffy-coats were obtained from
the local reference blood bank (Banc de Sang i Teixits, Barcelona).MolecularNALM6, HL60, K562, and 300.19 cell lines were purchased from
the American Type Culture Collection (ATCC). These four cell lines
were cultured in RPMI media + 10% fetal bovine serum (FBS) + an-
tibiotics. The HEK293T cell line was also purchased from the ATCC
(CRL-11268) and cultured in DMEM+ 10% FBS + antibiotics. All cell
lines were grown at 37C and 5% CO2. 300.19-hCD19 stable trans-
fected cells were produced using pUNO1-CD19 cDNA (InvivoGen,
San Diego, CA), as described in Massaguer et al.31
The A3B1 murine anti-CD19 mAb was generated at the Department
of Immunology (Hospital Clínic de Barcelona), and its anti-CD19
specificity was confirmed by our own recent (Figure 1) and previous
studies15 and several commercial distributors (Abcam, Immunostep,
and CliniSciences). Studies of A3B1 reactivity and blocking experi-
ment were performed as described in Romero et al.32
CAR19 Cloning and Lentivirus Production
The sequence corresponding to the variable light (VL) and variable
heavy (VH) regions of A3B1 antibody was extracted from A3B1 hy-
bridoma cells using Mouse Ig-Primer Set (Novagen, 69831-3). The
complete CAR19 sequence (including signal peptide, A3B1 scFv,
CD8 hinge, and transmembrane regions 4-1BB and CD3z) was syn-
thesized by GenScript and cloned into the third-generation lentiviral
vector pCCL (kindly provided by Dr. Luigi Naldini; San Raffaele Hos-
pital, Milan),20 under the control of EF1a promoter (Figure 2A). The
scFv sequence of the FMC63 antibody was extracted from patent
WO201207900033 and similarly cloned into the pCCL vector.
To produce lentiviral particles for pre-clinical studies, HEK293T cells
were transfected with our transfer vector (pCCL-EF1a-CAR19)
together with packaging plasmids pMDLg-pRRE (Addgene, 12251),
pRSV-Rev (Addgene, 12253), and envelope plasmid pMD2.G (Addg-
ene, 12259), using linear PEI molecular weight (MW) 25,000 (Poly-
sciences, 23966-1). Briefly, 6  106 HEK293T cells were plated
24 hr before transfection in 10-cm dishes. At the time of transfection,
14 mg total DNA (6.9 mg transfer vector, 3.41 mg pMDLg/pRRE, 1.7 mg
pRSV-Rev, and 2 mg pMD2.G) was diluted in serum-free DMEM.
35 mg PEI was added to the mix and incubated for 20 min at room
temperature. After incubation, DNA-PEI complexes were added
onto the cells cultured in 7 mL complete DMEM. Media were
replaced 4 hr later. Viral supernatants were collected 48 hr later
and clarified by centrifugation and filtration using a 0.45-mm filter.
Viral supernatants were concentrated using ultracentrifugation at
26,000 rpm for 2 hr 30 min. Virus-containing pellets were resus-
pended in complete XVivo15 media and stored at 80C until use.
Lentivirus Titration
The number of transducing units (TU/mL) was determined by the
limiting dilution method. Briefly, HEK293T cells were seeded 24 hr
before transduction. Then, 1:10 dilutions of the viral supernatant
were prepared and added on top of the cells in complete DMEM +
5 mg/mL Polybrene. Cells were trypsinyzed 48 hr later and labeled
with allophycocyanin (APC)-conjugated AffiniPureF(ab’)2 Fragment
Goat anti-mouse immunoglobulinG (IgG) (Jackson ImmunoResearchTherapy: Methods & Clinical Development Vol. 12 March 2019 141
Table 2. ARI-0001 Product Specification List and Acceptance Criteria
Parameter Method Acceptance Criteria ARI0001/01 ARI0001/02 ARI0001/03
Appearance visual inspection cloudy liquid solution cloudy liquid solution cloudy liquid solution cloudy liquid solution
Number of CAR19+ cells
Neubauer cell counting
and flow cytometry
35  106 cells for a 70-kg patient
(>0.5  106 cells/kg) 1,495  10
6 1,746  106 1,340  106
CAR19+ cells (%) flow cytometry R20% 26.0 41.9 39.7
CD3+ cells (%) flow cytometry R70% 97.9 98.6 98.6
Cell viability (%)
Neubauer cell counting
with trypan blue exclusion
R70% 97.9 98.1 98.0
Sterility microbial growth sterile sterile sterile sterile
Mycoplasma PCR absent absent absent absent
Endotoxin chromogenic assay %0.5 EU/mL %0.5 EU/mL %0.5 EU/mL %0.5 EU/mL
Adventitious viruses PCR absent absent absent absent
Number of transgene
copies/cell
real-time PCR %10 copies/cell 1.45 2.32 2.51
RCL (replication-competent
lentivirus)
real-time PCR absent absent absent absent
Cytotoxic potency flow cytometry
(a) NALM6 cell surviving fraction
using CART19 ratio E:T 1:1 <70%
or (b) difference in NALM6 cell
surviving fraction between CART19
versus untransduced T using ratio
E:T 4:1 >50%
(a) 14.9; (b) 90.9 (a) 40.4; (b) 64.6 (a) 43.0; (b) 67.0
Molecular Therapy: Methods & Clinical DevelopmentLaboratories, 115-136-072) before being analyzed by flow cytometry.
A dilution corresponding to 2%–20% of positive cells was used to
calculate viral titer.
T Cell Transduction and Culture Conditions
Healthy donor PBMCs were obtained from buffy-coats by density-
gradient centrifugation (Ficoll) after donation was consented,
following the instructions of the Ethics Committee. While monocytes
were eliminated by conventional plate adhesion, the remaining cells
were cultured in X-VIVO 15 Cell Medium (Cultek, BE02-060Q),
5% AB human serum (Sigma, H4522), penicillin-streptomycin
(100 mg/mL), and IL-2 (50 IU/mL; Miltenyi Biotec). Cells were then
activated and expanded for 24 hr using beads conjugated with CD3
and CD28 mAbs (Dynabeads, Gibco, 11131D), and they were trans-
duced 24 hr later with the lentivirus by overnight incubation in the
presence of polybrene (Santa Cruz Biotechnology, sc-134220) at
8 mg/mL. A period of cell expansion of 6–8 days was necessary before
conducting experiments. Three different cell transductions using
three different PBMC donors were used to conduct the experiments
in triplicate.
Flow Cytometry
The followingmAbs against human proteins, all fromBDBiosciences,
were used: CD3-fluorescein isothiocyanate (FITC), CD4-BV421,
CD8-APC, CD19-phycoerythrin (PE), and CD33-PE. 7-AAD was
used as a viability marker (Thermo Fisher Scientific, A1310). CAR19
expression was detected with an APC-conjugated AffiniPureF(ab’)2-
fragment goat-anti-mouse IgG (Jackson ImmunoResearch Labora-
tories, 115-136-072). Samples were run through the fluorescence-acti-142 Molecular Therapy: Methods & Clinical Development Vol. 12 Marchvated cell sorting flow cytometer BD FACSCanto II (BD Biosciences),
and data were analyzed using the BD FACSDiva Software.
In Vitro Assays of Anti-tumor Efficacy
CART19 (ARI-0001) or UT T cells were co-cultured for 16 hr, unless
otherwise indicated, with tumor target cell lines (NALM6 or HL60)
or primary B-ALL tumor cells, at different E:T ratios, maintain-
ing a fixed number of target cells. Then, cells were transferred to
TruCOUNT tubes (Becton Dickinson, 340334) and incubated with
mAbs against human CD4, CD8, CD19 (or CD33), and 7-AAD.
Cytotoxicity was determined by calculating the number of surviving
target cells (identified as 7-AAD-negative and CD19- or CD33-posi-
tive cells, for NALM6 andHL60 target cells, respectively). Acquisition
was stopped after a fixed number of beads was acquired and absolute
cell numbers were calculated, allowing comparison between different
E:T ratios. Co-culture supernatants were analyzed for cytokine pro-
duction (IFNg, TNF-a, and IL-10) by ELISA, following the manufac-
turer’s instructions (Becton Dickinson OptEIA). All experiments
were run in triplicate.
ARI-0001 cell proliferation in response to CD19 antigen was
measured using a CFSE assay. Briefly, ARI-0001 cells were labeled
with 1 mM CFSE, washed, and cultured with or without proliferating
stimuli (IL-2 50 U/mL, NALM6 or K562 cells). NALM6 or K562 cells
were added at an E:T ratio = 1:1. Assay was stopped after 96 hr and
cells were stained with anti-CD4 and anti-CD8. CFSE staining was
measured in CD4+ and CD8+ cells, and proliferating index (PI)
was calculated (PI = sum of number of cells in different genera-
tions/calculated number of original cells).2019
www.moleculartherapy.orgIn Vivo Xenograft Model of Anti-tumor Efficacy and Safety
Animal studies were approved by CEEA-UB, the competent ethics
committee for animal experimentation.
For the first experiment, 3-month-old NSG mice were infused intra-
venously (tail vein) with NALM6 tumor cells (1 106 cells/mice) ex-
pressing GFP and luciferase. Mice were then randomly allocated to
ARI-0001 cells (10  106/mice), UT cells (10  106 cells/mice), or
vehicle.
ARI-0001 or UT cells were infused 3 days after the infusion of
NALM6. Tumor growth was evaluated weekly by bioluminescence
imaging (Hamamatsu detector) after the intravenous administration
of D-luciferin. Mice were sacrificed at days 16–17, and tumor burden
was measured in blood and bone marrow samples by flow cytometry.
The second experiment was designed to compare the two CAR19
constructs (A3B1 and FMC63). The 3-month-oldNSGmicewere irra-
diated with 2 Gy at day 8. NALM6 tumor cells (1  106 cells/mice)
expressing GFP and luciferase were infused intravenously (tail vein)
the following day, except in one mouse (control mouse). Tumor cells
were allowed to engraft for several days.Mice were randomly allocated
toNALM6+T (n= 3), NALM6+A3B1 (n = 4), andNALM6+FMC63
(n = 3) groups. 5  106 cells/mice were infused intravenously (UT
T cells, T A3B1, or T FMC63). Bioluminescence images were taken
twice a week to follow disease progression. A blood sample was taken
at day 12 to measure disease burden and T cell expansion by flow
cytometry. Bioluminescence images were quantified using ImageJ.
Patient-Scale ARI-0001 Cell Production
Leukocytapheresis from healthy donors was obtained in the Apher-
esis Unit at the Hospital Clínic de Barcelona with informed consent
and approved by the Ethics Committee of our hospital. Apheresis
procedures were performed using the Amicus device (Fresenius
Kabi, Lake Zurich, IL). A minimum of 1  108 T cells diluted in
50 mL plasma was required. Cells were cultured in the CliniMACS
Prodigy system (Miltenyi Biotec) using TexMACS media supple-
mented with 3% human AB serum and with IL-7 and IL-15 (Miltenyi
Biotec 170-076-111 and 170-076-114, respectively). For T cell activa-
tion, TransACT GMP Grade (Miltenyi Biotec, 170-076-156) was
used.
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